- Report
- January 2025
- 85 Pages
Global
From €3500EUR$3,921USD£3,032GBP
- Report
- November 2022
- 79 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- October 2022
- 286 Pages
Global
From €2390EUR$2,500USD£2,001GBP
- Report
- July 2022
- 67 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- June 2022
- 32 Pages
Global
From €1912EUR$2,000USD£1,601GBP
- Report
- July 2024
- 216 Pages
Global
From €2538EUR$2,655USD£2,125GBP
Ranibizumab is a monoclonal antibody used to treat optical disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO). It is administered as an intravitreal injection, and works by inhibiting the activity of vascular endothelial growth factor (VEGF), which is responsible for the growth of abnormal blood vessels in the eye. Ranibizumab is the first anti-VEGF drug approved by the US Food and Drug Administration (FDA) for the treatment of wet AMD, and is now widely used in the treatment of other optical disorders.
Ranibizumab is available in both branded and generic forms, and is marketed by a number of pharmaceutical companies, including Novartis, Regeneron, Genentech, and Allergan. Show Less Read more